Understanding Off-Label Drug Use in Cancer Treatment
In the complex landscape of oncology, doctors often use medications in ways that aren’t explicitly listed on the drug’s official packaging. This practice, known as “off-label” use, is a common and often essential part of cancer care. While it may sound unconventional, off-label prescribing allows physicians to tailor treatments to a patient’s specific genetic profile or cancer type when standard options are exhausted.
- Off-label use means prescribing a drug for a purpose, dose, or patient group not approved by the FDA.
- It is a frequent practice in cancer treatment to provide novel therapeutic options.
- Recent large-scale evaluations, such as a study involving over 1,600 patients in the Netherlands, suggest that off-label targeted therapies can provide durable benefits for some patients.
- While beneficial, off-label use carries specific medico-legal risks for healthcare providers.
What Exactly Are Off-Label Drugs?
To understand off-label use, it’s important to understand how drugs enter the market. In the United States, drugs can only be legally sold after the Food and Drug Administration (FDA) approves them. This approval happens after rigorous research proves the drug is safe and effective for a very specific use.
The “label” is the package insert that describes what the drug is made of, how it works, the research that led to its approval, and potential side effects. When a doctor prescribes a drug for a purpose not described on that label, it’s considered “off-label.”
Common Examples of Off-Label Use
Off-label prescribing isn’t just about using a drug for a different disease. It can include:
- Using a drug approved for one type of cancer to treat a different type of cancer.
- Administering the medication at a different dose or frequency than the label suggests.
- Prescribing a drug to a child when it was only approved for adults.
The Role of Off-Label Use in Oncology
Off-label drug use is very common in cancer treatment. In many cases, the “usual care” for a specific stage or type of cancer actually includes the off-label use of one or more drugs. This flexibility is crucial because cancer is highly variable; what works for one patient may not work for another, even if they have the same diagnosis.
Recent evidence highlights the potential of this approach. The largest published prospective evaluation of off-label targeted cancer therapies, involving over 1,600 patients in the Dutch system, demonstrated that more patients could benefit from existing drugs when used off-label, often delivering a durable benefit for some individuals.
Risks and Regulations
While the FDA controls which drugs are approved for sale, it doesn’t control how doctors choose to use those drugs for their patients. Once a drug is approved, physicians have the discretion to prescribe it for any purpose they believe makes sense for the patient.
Yet, this discretion comes with challenges. Using medications or medical devices off-label can lead to medico-legal risks for physicians. Because these uses aren’t backed by the same formal FDA approval process, doctors must carefully manage the risks and ensure the decision is based on sound medical reasoning.
From Off-Label to Approved
An off-label use can eventually turn into an approved use. This happens if the company that manufactures the drug conducts new research studies to prove the treatment is safe and effective for the new purpose and subsequently obtains FDA approval. However, some companies may choose not to invest the time and money required for these additional studies.
Frequently Asked Questions
Is off-label prescribing legal?
Yes. In the United States, once the FDA approves a drug for one use, doctors can legally prescribe it for other purposes they deem appropriate for their patients.
Why don’t all effective uses get FDA approval?
Obtaining additional approvals requires expensive and time-consuming research studies. Some pharmaceutical companies may decide not to invest the resources necessary to gain a new label indication.
How do doctors decide to use a drug off-label?
Clinicians often rely on updated classifications and exploration of anticancer drug categories to identify novel therapeutic options and improve patient management.
Looking Ahead
As our understanding of cancer genetics grows, the identification of novel therapeutic options through off-label use will likely continue to evolve. By refining the classification of these uses, researchers and clinicians can better identify which patients are most likely to benefit, potentially turning today’s off-label successes into tomorrow’s standard-of-care treatments.
Related reading